TCON TRACON Pharmaceuticals Inc.

-0.02  -2%
Previous Close 1.05
Open 1.04
Price To Book 1.07
Market Cap 30767467
Shares 29,871,327
Volume 157,383
Short Ratio
Av. Daily Volume 401,863

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data to be presented at IASLC 2019 February 20-23, 2019.
TRC105 + Opdivo
Non-small cell lung cancer (NSCLC)
Phase 1b enrollment to be completed 2018.
TRC105 + Avastin
Non-Squamous Cell Lung Cancer
Phase 2 data due 2020.
Prostate cancer
Phase 2 data due mid-2019.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 1b/2 data at GI ASCO January 2019 noted partial response by RECIST 1.1 occurred in 3 of 15 (20%).
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 data December 21, 2018 did not meet primary endpoint.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 primary endpoint not met - November 19, 2018.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2019.
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017. Interim analysis due 1Q 2019.
Angiosarcoma cancer

Latest News

  1. TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019
  2. TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma
  3. Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  4. Stocks to Watch Before The Opening Bell on December 27, 2018
  5. The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede
  6. TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer
  7. TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors
  8. TRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma
  9. TRACON Pharmaceuticals and I-Mab Biopharma Reschedule Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
  10. TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
  11. TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
  12. Circulating Tumor Cells Detected From Angiosarcoma Cancer Patients With Use Of ApoStream® Technology In A First-of-its-kind Study
  13. Edited Transcript of TCON earnings conference call or presentation 7-Nov-18 9:30pm GMT
  14. Tracon: 3Q Earnings Snapshot
  15. The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie